NDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EQUAGESIC (aspirin; meprobamate) by PharmaIN is clinical pharmacology meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Approved for anxiety. First approved in 1960.
Drug data last refreshed 9h ago · AI intelligence enriched 11h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EQUAGESIC is an oral fixed-dose combination tablet containing aspirin and meprobamate, approved in 1960 for anxiety treatment. Meprobamate acts as a central nervous system depressant affecting the thalamus and limbic system, while aspirin provides nonnarcotic analgesia with antipyretic and anti-inflammatory properties. This combination addresses anxiety with concurrent pain relief.
LOE Approaching
Product is in late-stage market maturity with minimal commercial investment; teams are likely focused on retention and transition planning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Aspirin is a nonnarcotic analgesic with antipyretic and anti-inflammatory…
Indications (1)
Career Relevance
EQUAGESIC offers minimal career development opportunity as a legacy product in LOE stage with zero linked job openings and declining commercial investment. Working on this product involves managing decline rather than building growth—suitable only for transitional roles or those seeking stability over advancement.
Worked on EQUAGESIC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.